The role of albendazole in programmes to eliminate lymphatic filariasis.
about
Albendazole for lymphatic filariasisSome observations on the effect of Daflon (micronized purified flavonoid fraction of Rutaceae aurantiae) in bancroftian filarial lymphoedemaTolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co-administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hoTreatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasisImpact of two rounds of mass drug administration using diethylcarbamazine combined with albendazole on the prevalence of Brugia timori and of intestinal helminths on Alor Island, IndonesiaMass ivermectin treatment for onchocerciasis: lack of evidence for collateral impact on transmission of Wuchereria bancrofti in areas of co-endemicity.Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasisIdentification and ultrastructural characterization of the Wolbachia symbiont in Litomosoides chagasfilhoi.Resistance and susceptibility to filarial infection with Litomosoides sigmodontis are associated with early differences in parasite development and in localized immune reactionsModel-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.Linking disease control programmes in rural Africa: a pro-poor strategy to reach Abuja targets and millennium development goalsTropical medicine.Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia.Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control.Transmission intensity and human immune responses to lymphatic filariasis.Anti-filarial activity of novel formulations of albendazole against experimental brugian filariasis.A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, MaliGlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.The argument for integrating vector control with multiple drug administration campaigns to ensure elimination of lymphatic filariasisComparative efficacy of ivermectin and levamisole for reduction of migrating and encapsulated larvae of Baylisascaris transfuga in miceLymphatic filariasis elimination: progress in global programme development.The Global Programme to Eliminate Lymphatic Filariasis: History and achievements with special reference to annual single-dose treatment with diethylcarbamazine in Samoa and FijiImpact on prevalence of intestinal helminth infection in school children administered with seven annual rounds of diethyl carbamazine (DEC) with albendazole.Chemotherapy for lymphatic filariasis: progress but not perfection.Mass drug administration coverage evaluation survey for lymphatic filariasis in bagalkot and gulbarga districtsTreatment strategies underpinning the global programme to eliminate lymphatic filariasis.Albendazole for the control and elimination of lymphatic filariasis: systematic review.Public-private partnerships in blindness prevention: reaching beyond the eye.A critical appraisal of molecular xenomonitoring as a tool for assessing progress toward elimination of Lymphatic Filariasis.Mathematical models for lymphatic filariasis transmission and control: Challenges and prospects.Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazoleCurrent practices in the management of lymphatic filariasis.Prospects for the control of neglected tropical diseases by mass drug administration.The development of albendazole for lymphatic filariasis.Diurnally subperiodic filariasis in India-prospects of elimination: precept to action?Neglected tropical diseases: survey and geometry of randomised evidence.Challenges in drug discovery for novel antifilarials.Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.Participation in three consecutive mass drug administrations in Leogane, Haiti.
P2860
Q24245688-09B50F9F-03FA-44F8-94E8-F2F698EA4DF4Q24791615-CEB7AD47-F795-42DF-8C8A-D7815BD50F1AQ24793634-2CE01E3D-FE8E-4B02-88BD-D2A472D19CB2Q24799885-5F4C2282-7176-4811-8C60-A2F93F5D1C90Q24812360-FF5F68F8-13D8-4306-AB09-1389E1D8148BQ24813874-A5357C6B-1DBC-48AE-97ED-41A73FB4F30BQ28484840-94D76319-F626-41AE-BD54-954C4FF0B566Q30620100-A51D2CFD-8F23-4C1B-A39E-CD4B11629A65Q31028656-F5E631F1-DE2C-43F2-B435-FBEAF9B4D051Q31038122-C6F1AAFF-B1B8-47B1-A39E-BA0DF1549B1FQ33777060-EE420FFB-91DE-4727-B6CF-CF28A2BF4317Q33817432-88A9F630-6751-4BAB-B2B4-7DDDA338073AQ34084013-2AF0448E-F68D-4346-93F7-DD7985F078EEQ34281491-8E8ABAC1-D087-4B07-90FC-759A19B43AAAQ34319424-75ECB2D8-6550-4C0C-A1D6-295AF3125FC5Q34578406-EDFB0042-0E82-40A2-8244-2EEC8D26893CQ34723495-749B1FE8-9C24-4269-956A-0A5F5FBC8C96Q35008719-A606D068-1A45-479E-B830-377C01AF3BC5Q35017384-368FB794-760F-41BB-A68C-8508B2E5EAECQ35062273-D10BBE8F-5655-4D40-A65B-C295DA7A8CB5Q35083183-4A0075FD-51BE-42D3-8E69-8AB8FB4C51CDQ35325544-D6A875DC-4FB4-40D7-AEDD-2B0E1A1AF44BQ35640881-E91C0842-E6DA-456F-95CD-629229FB4DA3Q35917282-DAF2F7EB-3D8C-4FEF-83D1-A57EC0185417Q35992966-223ADBCB-AA03-41A2-B2A1-BC54DDC3ACE8Q36066068-51536956-9582-453C-90FD-EED1BEE319CFQ36245872-93987D84-7EE2-4D8D-A648-CE4D65D9498DQ36320399-6E304256-3242-413E-9502-0D87E4EC99A1Q36377537-251BCBAA-F03E-48EA-A2AB-54817A90420CQ36509658-88BBAF8F-5ECC-4292-AC52-462EC95E733CQ37254795-FF1EDDB2-D659-4DE3-80AC-EA78743E591BQ37471097-989E1A25-27CA-4612-B358-24EF4B82524BQ37503357-1822A0C0-5AA8-45FD-B74D-52BD96F85E94Q37557676-C4B8B893-AB6C-49AB-A640-52F007A80C75Q37618340-7ADAE5B5-6E0C-4BD2-BA1F-F95F4616884CQ37834370-69DA9732-C41C-4F0F-9260-1BF6EF3654D1Q38054293-254DA066-4371-4134-9E4C-E56559DEBD59Q39531590-6518C851-4FB8-4805-A35B-95FB4FAC06F6Q39687003-B9E58E68-2647-40DF-AACE-49AAD309699BQ39758744-5E3FA426-691A-4F7B-9BB5-CB48451D998F
P2860
The role of albendazole in programmes to eliminate lymphatic filariasis.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The role of albendazole in programmes to eliminate lymphatic filariasis.
@ast
The role of albendazole in programmes to eliminate lymphatic filariasis.
@en
type
label
The role of albendazole in programmes to eliminate lymphatic filariasis.
@ast
The role of albendazole in programmes to eliminate lymphatic filariasis.
@en
prefLabel
The role of albendazole in programmes to eliminate lymphatic filariasis.
@ast
The role of albendazole in programmes to eliminate lymphatic filariasis.
@en
P2093
P1476
The role of albendazole in programmes to eliminate lymphatic filariasis.
@en
P2093
P304
P356
10.1016/S0169-4758(99)01486-6
P577
1999-09-01T00:00:00Z